Evaluation of<i> hsa-miR-29a-3p</i> expression and diazepam biotransformation via<i> CYP2C19</i> in alcohol withdrawal syndrome

Tezcan T., Özkan-Kotiloğlu S., Yıldırım M. A., Danışman M., Bozmaoğlu H. C., Tok K. C., ...Daha Fazla

ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, cilt.120, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 120
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1016/j.etap.2025.104861
  • Dergi Adı: ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, Environment Index, Greenfile, MEDLINE
  • Anahtar Kelimeler: Alcohol withdrawal syndrome, CYP2C19, Diazepam, hsa-miR-29a-3p, Pharmacoepigenetics
  • Ankara Üniversitesi Adresli: Evet

Özet

This study investigated whether hsa-miR-29a-3p expression affects diazepam (DZP) metabolism by modulating CYP2C19 gene expression in patients with alcohol withdrawal syndrome (AWS). Blood samples were obtained from 75 male AWS patients. hsa-miR-29a-3p expression was quantified using qRT-PCR, and plasma DZP and its active metabolite nordiazepam (NDZP) levels were measured via HPLC. No significant correlations were found between hsa-miR-29a-3p expression and DZP dose, plasma DZP/NDZP levels, dose-adjusted or weight-adjusted concentrations, or the metabolite-to-parent drug ratio. However, hsa-miR-29a-3p expression levels were significantly higher in patients exhibiting confusion (p = 0.016) and excessive fatigue (p = 0.039). Although hsa-miR29a-3p did not appear to influence diazepam biotransformation directly, this study is the first to report a potential link between elevated hsa-miR-29a-3p expression and neuropsychiatric symptoms in AWS, suggesting a possible role of this microRNA in the clinical presentation of alcohol withdrawal.